Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 9.5%

Grifols, S.A. (NASDAQ:GRFS) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 5,530,000 shares, a decrease of 9.5% from the August 15th total of 6,110,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is presently 3.2 days. Currently, 2.2% of the shares of the stock are short sold.

Grifols Price Performance

Grifols stock traded down $0.16 during mid-day trading on Wednesday, hitting $8.74. The stock had a trading volume of 560,932 shares, compared to its average volume of 2,124,579. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06. The firm’s 50 day moving average is $8.15 and its 200 day moving average is $7.29. Grifols has a one year low of $5.30 and a one year high of $12.15.

Grifols (NASDAQ:GRFS) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. On average, sell-side analysts expect that Grifols will post 0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Grifols

Large investors have recently made changes to their positions in the company. Cohen Investment Advisors LLC bought a new stake in shares of Grifols in the first quarter worth about $80,000. AQR Capital Management LLC bought a new stake in shares of Grifols in the second quarter worth about $89,000. Morningstar Investment Services LLC bought a new stake in shares of Grifols in the fourth quarter worth about $186,000. Cetera Advisors LLC bought a new stake in shares of Grifols in the first quarter worth about $147,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Grifols by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 9,350 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.